Patents Assigned to RNAimmune, Inc.
  • Patent number: 12280105
    Abstract: Provided herein is a ribonucleic acid (RNA) encoding a spike (S) protein or an immunogenic fragment thereof of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) comprising at least one non-naturally occurring amino acid mutation. In some embodiments, the S protein is derived from a delta variant. Additionally provided are relevant polynucleotides, vectors, cells, compositions, kits, production methods and methods of use.
    Type: Grant
    Filed: February 9, 2024
    Date of Patent: April 22, 2025
    Assignee: RNAIMMUNE, INC.
    Inventors: Neeti Ananthaswamy, Yong-Sik Bong, David Brown, Renxiang Chen, Ju Hyeong Jeon, Zhifeng Long, Dong Shen, Chun Lu, Patrick Y. Lu, Shenggao Tang, Jiaxi He, Ziyang He
  • Patent number: 12280104
    Abstract: Provided herein is a ribonucleic acid (RNA) encoding a spike (S) protein or an immunogenic fragment thereof of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) comprising at least one non-naturally occurring amino acid mutation. In some embodiments, the S protein is derived from an Omicron variant. Additionally provided are relevant polynucleotides, vectors, cells, compositions, kits, production methods and methods of use.
    Type: Grant
    Filed: October 31, 2023
    Date of Patent: April 22, 2025
    Assignee: RNAIMMUNE, INC.
    Inventors: David Brown, Yong-Sik Bong, Neeti Ananthaswamy, Naihsuan C. Guy, Dong Shen
  • Publication number: 20240374697
    Abstract: Compositions and methods are provided for potent mRNA vaccines for treatment of cancer with mutations in ras gene family multiplexed with TP53. The compositions include a pharmaceutical composition containing mRNA molecules encoding multiple peptides of a group of somatic mutations together with a pharmaceutically acceptable carrier. Methods for stimulating system immune responses and treatment are provided, including intratumoral, intravenous, intramuscular, intradermal, and subcutaneous injection.
    Type: Application
    Filed: December 8, 2023
    Publication date: November 14, 2024
    Applicant: RNAimmune, Inc.
    Inventors: Dong SHEN, David BROWN
  • Publication number: 20240370011
    Abstract: Provided herein is a ribonucleic acid (RNA) encoding a fusion glycoprotein (F) protein or an immunogenic fragment thereof of a respiratory syncytial virus (RSV) comprising at least one non-naturally occurring amino acid mutation. Additionally provided are relevant polynucleotides, vectors, cells, compositions, kits, production methods and methods of use.
    Type: Application
    Filed: July 23, 2024
    Publication date: November 7, 2024
    Applicant: RNAimmune, Inc.
    Inventors: David Brown, Neeti Ananthaswamy, Renxiang Chen
  • Publication number: 20240294580
    Abstract: Provided herein is a ribonucleic acid (RNA) encoding a fusion glycoprotein (F) protein or an immunogenic fragment thereof of a respiratory syncytial virus (RSV) comprising at least one non-naturally occurring amino acid mutation. Additionally provided are relevant polynucleotides, vectors, cells, compositions, kits, production methods and methods of use.
    Type: Application
    Filed: May 16, 2024
    Publication date: September 5, 2024
    Applicant: RNAimmune, Inc.
    Inventors: David Brown, Neeti Ananthaswamy, Renxiang Chen
  • Publication number: 20240226275
    Abstract: Provided herein is a ribonucleic acid (RNA) encoding a spike (S) protein or an immunogenic fragment thereof of a severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) comprising at least one non-naturally occurring amino acid mutation. In some embodiments, the S protein is derived from a delta variant. Additionally provided are relevant polynucleotides, vectors, cells, compositions, kits, production methods and methods of use.
    Type: Application
    Filed: February 9, 2024
    Publication date: July 11, 2024
    Applicant: RNAimmune, Inc.
    Inventors: Neeti Ananthaswamy, Yong-Sik Bong, David Brown, Renxiang Chen, Ju Hyeong Jeon, Zhifeng Long, Dong Shen, Chun Lu, Patrick Y. Lu, Shenggao Tang, Jiaxi He, Ziyang He
  • Patent number: 12029786
    Abstract: Compositions and methods are provided for potent mRNA vaccines for prevention and treatment of 2019 novel Coronavirus (2019-nCoV) infections. The compositions include a pharmaceutical composition containing one or more mRNA molecules encoding spike protein epitopes, including mutated epitopes, or mRNA cocktails that encode critical viral genes together with pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers. Methods for stimulating system immune responses and treatment are provided, including subcutaneous, intraperitoneal and intramuscular injections.
    Type: Grant
    Filed: February 8, 2021
    Date of Patent: July 9, 2024
    Assignee: RNAimmune, Inc.
    Inventors: Shenggao Tang, Dong Shen, Chun Lu, Ziyang He, Jiaxi He, Patrick Y. Lu
  • Publication number: 20240156947
    Abstract: Provided herein is a ribonucleic acid (RNA) encoding a spike (S) protein or an immunogenic fragment thereof of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) comprising at least one non-naturally occurring amino acid mutation. In some embodiments, the S protein is derived from an Omicron variant. Additionally provided are relevant polynucleotides, vectors, cells, compositions, kits, production methods and methods of use.
    Type: Application
    Filed: October 31, 2023
    Publication date: May 16, 2024
    Applicant: RNAimmune, Inc.
    Inventors: David BROWN, Yong-sik BONG, Neeti ANANTHASWAMY, Naihsuan C. GUY, Dong SHEN
  • Publication number: 20230355527
    Abstract: Novel lipids, compositions, and methods of using the novel lipids and compositions are disclosed. Three-component lipid nanoparticle compositions comprising the novel lipids or other types of lipids, and methods of using the three-component lipid nanoparticle compositions are disclosed. Three-component lipid nanoparticle compositions contain a steroidal or structural lipid-containing component, a PEGylated lipid-containing component, a cationic or ionizable lipid-containing component, and are free of phospholipids. Pharmaceutical formulations including the three-component lipid nanoparticle compositions and further including therapeutic and/or prophylactics such as mRNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs.
    Type: Application
    Filed: April 7, 2023
    Publication date: November 9, 2023
    Applicant: RNAimmune, Inc.
    Inventors: Evan Michael Lewoczko, Renxiang Chen, Neeti Ananthaswamy, Dong Shen
  • Publication number: 20230108926
    Abstract: Compositions and methods are provided for potent mRNA vaccines for prevention and treatment of 2019 novel Coronavirus (2019-nCoV) infections. The compositions include a pharmaceutical composition containing one or more mRNA molecules encoding spike protein epitopes, including mutated epitopes, or mRNA cocktails that encode critical viral genes together with pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers. Methods for stimulating system immune responses and treatment are provided, including subcutaneous, intraperitoneal and intramuscular injections.
    Type: Application
    Filed: February 8, 2021
    Publication date: April 6, 2023
    Applicant: RNAimmune, Inc.
    Inventors: Shenggao TANG, Dong SHEN, Chun LU, Ziyang HE, Jiaxi HE, Patrick Y. LU